In a clinical trial, a patient who received MAGE-A3 specific TCR-T cell therapy had a preliminary remission of esophageal cancer at 1 month, but suffered a serious tumor progression at 2 months and died shortly thereafter (63). This evidence concerns the gene MAGEA3 and esophageal cancer.